Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Inclusion Criteria: * Male, age between (both inclusive) 18 and 55 years at the time of signing inform consent * Overweight or obese but otherwise healthy male subjects; BMI of between or equal to 27.0 and 35.0 kg/m\^2 Exclusion Criteria: * Thyroid stimulating hormone values outside 0.4-6.0 mIU/l * HbA1c (glycated hemoglobin) above or equal to 6.5% * Any clinically relevant ECG (electrocardiogram) findings (e.g. 2nd or 3rd degree AV-block), in particular subjects with repeated demonstration of a QTcF (QT interval corrected by Fridericia formula) interval above 430 ms * A history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) * The use of concomitant medications that prolong the QT/QTc interval * Obesity caused by endocrinology disorders (e.g. Cushing's Syndrome) * Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 * Calcitonin above 50 ng/L * History of pancreatitis (acute or chronic)